The month brought a heart-safety result and one EU recommendation, not a new weight-loss record
Between Sep 24 and Oct 23, 2026, the GLP-1 market moved through safety data, one European recommendation and enforcement, while sales and prices changed little. Every fact is judged against Oct 24, 2026; items dated before Sep 24 are context.
Five conclusions
The month brought a heart-safety result, not a new weight-loss record
In ACHIEVE-4, Lilly's oral Foundayo (orforglipron) met non-inferiority to insulin glargine on cardiovascular events, with a MACE-4 hazard ratio of 0.84 (95% CI 0.59-1.20) in 2,749 adults with type 2 diabetes; superiority was not shown. Novo's CagriSema beat tirzepatide 5 mg, 12.4% against 9.1%, but at a low comparator dose, and at the top dose it missed non-inferiority in REDEFINE 4. Retatrutide's 28.3% at 80 weeks remains the highest figure.
The only new decision was a recommendation, and access runs through national launches
On Oct 15 the EMA's CHMP backed Foundayo for obesity and type 2 diabetes; the European Commission decision is pending, and about Dec 21 is our estimate from a 67-day norm. Novo said on Sep 30 that its Wegovy pill is launched in the US, UAE, UK and Germany, while a Sept 2026 tracker found 2 of 16 European countries on the market and 13 approved but not launched. CagriSema's US decision is expected in Q4 2026.
Lilly leads, but Q3 results arrive after the window
Lilly reports on Oct 29 and Novo on Nov 4. In Q2 Mounjaro and Zepbound sold $9.9B and $4.9B, about 1.9 times Novo's $7.8B injectable semaglutide, and Lilly held about 61% of US prescriptions. Foundayo made $98M in Q2.
Supply news was enforcement, not scarcity
Apothecary Pharma recalled 22 tirzepatide lots plus one NAD+ lot for lack of sterility assurance, classed Class II on Oct 8, and FDA's Sept 18 letter to Empower called its products "essentially copies". Neither drug appears on FDA's shortage list, and the plant figures, such as Lilly's more than $20B for injectables, are cumulative commitments with no in-window announcement.
The price now depends on the channel
Medicare's Bridge, in effect since Jul 1, has a $50 copay against a $245 net price, and cash buyers pay $349 for the Wegovy pen or $149 for the starter Wegovy pill. Commercial coverage is retreating: Zepbound is uncovered for 60% of commercial lives, and at least 10% of covering employer plans may drop coverage in 2027.
Obesity drugs at a glance
| Drug | Item | Date | Status | Source |
|---|---|---|---|---|
| Foundayo (orforglipron)Eli Lilly | CHMP positive opinion, obesity and type 2 diabetes | Oct 15, 2026 | Opinion adopted; EC decision pending | EMA |
| Foundayo (orforglipron)Eli Lilly | ACHIEVE-4: MACE-4 HR 0.84 vs insulin glargine | Sept 30, 2026 | Presented and published | Lilly (company release) |
| Wegovy pillNovo Nordisk | Launched in US, UAE, UK and Germany | Sep 30, 2026 | ShippingCompany statement | Novo (PRNewswire) |
| CagriSemaNovo Nordisk | REIMAGINE 5: 12.4% vs 9.1% (tirzepatide 5 mg) | Sept 2026 (day not stated) | Company-reported | Yahoo Finance |
| CagriSemaNovo Nordisk | FDA weight-management decision expected | Q4 2026 | Pending; no PDUFA date published | pepglp1 |
| Mounjaro / ZepboundEli Lilly | Q2 sales $9.9B / $4.9B | Q2 2026 | Reported | Pharmaceutical Technology |
| RetatrutideEli Lilly | BLA submission planned | Q1 2027 | PlannedAnnounced Jul 23, 2026, via glp3.wiki | glp3.wiki |
| Wegovy, Zepbound, FoundayoNovo Nordisk, Eli Lilly | Medicare Bridge: $50 copay, $245 net price | Jul 1, 2026 to Dec 31, 2027 | In effect | MyClearMatch |
| Wegovy penNovo Nordisk | Cash price $349 per month | Oct 19, 2026 | In effect | GLP Chart |
Status labels are shown as stated; company-reported rows come from the company's own release or statement.
No new efficacy record arrived: the data were a heart-safety result, a low-dose win and the first regain trials
Module 1 summarises the month; this module gives the trial data behind it, each with its basis and date. Separate trials are never head-to-head, whatever the gap.
Readouts at a glance
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| CagriSema 1/1 mg vs tirzepatide 5 mg, REIMAGINE 5 (Ph3, T2D, 60 wk) | 12.4% vs 9.1% | Sept 2026 (day not stated) | Company-reported | Yahoo Finance |
| CagriSema, REDEFINE 1 post hoc, 2,309 women | ~25% vs 3% placebo | Oct 20, 2026 | Conference, post hoc | pharmaphorum |
| Orforglipron vs insulin glargine, ACHIEVE-4 (Ph3, n=2,749) | MACE-4 HR 0.84 | Sept 30, 2026 | ConferenceLancetRelease | Lilly |
| Eloralintide + tirzepatide (Ph2, T2D, 48 wk) | 23.3% vs 14.8% | Late Sept 2026 | Company-reported | Healthcount |
| Retatrutide 12 mg (Ph3, T2D, 80 wk) | 20.8% | EASD, Sept 28-Oct 2 (day not stated) | Conference | Obesity Medicine Visuals |
| Revita after GLP-1 stop, REMAIN-1 (6 mo) | regain 5.1% vs 8.2% sham | Oct 16, 2026 | Company-reported | Fractyl |
| Meals or app after GLP-1 stop (pilot, n=39) | regain ~3.6% vs ~11% | Oct 7, 2026 | Peer-reviewed pilot | News-Medical |
Detail by sponsor and topic
CagriSema 1.0/1.0 mg gave an estimated 12.4% weight loss against 9.1% for tirzepatide 5 mg, a gap of 12.4 - 9.1 = 3.3 points (Sept 2026, day not stated). HbA1c fell 1.71% against 1.67%, meeting non-inferiority. This is a company announcement with no peer-reviewed paper or safety table in the material.
In REDEFINE 4 (Feb 2026; 809 adults; 84 weeks) CagriSema 2.4/2.4 mg missed non-inferiority to tirzepatide 15 mg: 23% against 25.5% on treatment, according to pepglp1. In REDEFINE 9 the 1/1 mg dose gave an estimated 21% at 68 weeks against 2.0% for placebo, a 19-point gap (21 - 2.0).
Women (n=2,309) at 68 weeks against placebo. Conference, post hoc analysis.
The Motley Fool notes the subgroup figures assume everyone took the drug as directed. CagriSema's best numbers come from favourable subgroups or comparators; its US decision date is in module 3.
Phase 3, open-label, in 2,749 adults with type 2 diabetes and raised cardiovascular risk. Lilly released the detail on Sept 30, 2026, as it was presented at EASD and published in The Lancet. MACE-4 had a hazard ratio of 0.84 (95% CI 0.59-1.20), event rates 4.2% against 5.0%, which met the non-inferiority bar (upper limit below 1.8). MACE-3 was 0.77 (p=0.181), so superiority was not shown. Lilly's 53% and 57% lower cardiovascular and all-cause death (HR 0.47, 0.43) were not controlled for type 1 error.
At 52 weeks weight fell 8.8% against a 1.7% rise on Lilly's efficacy estimand, and -7.79% against +1.12% on the treatment-regimen estimand (Medscape); we quote both. Gastrointestinal events were 62.1% against 14.2%; adverse-event discontinuation was 15.4% against 5.4% over the full trial, while Lilly gives 10.6% for the first 52 weeks, so the windows differ. Level 2 or 3 hypoglycaemia was 6.8% against 19.2%.
Top combination against tirzepatide 15 mg; placebo 3.0%. An 8.5-point gap (23.3 - 14.8). Company-reported (Healthcount).
Retatrutide reached EASD with a completed Phase 3 programme: 20.8% at 12 mg after 80 weeks in obesity with type 2 diabetes (conference). Lilly plans a US filing in Q1 2027, according to glp3.wiki. ATTAIN-OUTCOMES, powered for benefit, completes in 2031. Sources disagree on the ACHIEVE-4 dose ceiling, so we state none. Leerink's $23 billion 2035 sales view for eloralintide is an estimate.
A sham-controlled trial of Revita, a duodenal ablation device, after GLP-1 therapy stopped (6 months). Regain was 5.1% against 8.2% (p=0.0023), a (8.2 - 5.1) / 8.2 = 38% relative reduction. The release lists arms of 176 and 74 against N=308 without explaining the gap (176 + 74 = 250). The 53% reduction at 20 cm or more is post hoc. The second co-primary endpoint reads out at 12 months, planned for Q1 2027.
The only randomized behavioural data: 39 people given meals (n=13), the Noom app (n=12) or usual care (n=14) for four months. Model-estimated regain was about 3.6% in both active arms against about 11% for usual care, roughly 7 points apart. Weight was exploratory, prior weight loss differed by arm, and follow-up was short.
Extra weight lost by patients who switched to the Wegovy pill and stayed three more months. Non-randomized real-world data.
No Phase 3 efficacy data yet. Its trial AMAZE 7 was registered to start Sept 22, and AMBIENCE on Oct 26, 2026.
The only new decision was a CHMP opinion, and approval no longer limits oral GLP-1 access in Europe
Module 2 covered what the trials showed; this module covers what regulators and launch teams did with them between Sep 24 and Oct 23, 2026. Status is judged against Oct 24, 2026.
Decision and launch tracker (as of Oct 24, 2026)
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| Foundayo (orforglipron), EU | CHMP positive opinion: obesity and type 2 diabetes, adults | Oct 15, 2026 | Opinion adopted; EC decision pending | EMA |
| Foundayo, EC decision | "Normally within 67 days", so by about Dec 21 | from Oct 15 | Estimate | Syenza |
| Foundayo, US | FDA approval for obesity; T2D indication pending | Apr 1, 2026 | In effect (obesity)T2D filing date not stated | NowPatient; PharmExec |
| Foundayo, UK | Approved for weight loss and T2D | Aug 10, 2026 | In effect; on sale privately | Good Fiber; Medscape |
| Wegovy pill, EU | Central authorisation, weight management only | Jul 14, 2026 | In effect | Good Fiber |
| Wegovy pill, launches | US, UAE, UK, Germany | Sep 30, 2026 | ShippingCompany statement | Novo (PRNewswire) |
| Wegovy pill, China | NMPA accepted the application | Aug 27, 2026 | Reported (filing, not approval) | Law-firm page |
| CagriSema, US | FDA weight-management decision expected Q4 2026 | filed Dec 2025 | Pending; no PDUFA date published | pepglp1; pharmaphorum |
Wegovy pill status in 16 European countries
European countries had the Wegovy pill on sale in Sept 2026, while Novo's Sep 30 release lists launches in only four markets worldwide: the US, UAE, UK and Germany.
Detail by product
The EMA's CHMP recommended a marketing authorisation for Foundayo (Eli Lilly Nederland B.V.), an oral, non-peptide GLP-1 receptor agonist. EMA's own release is the primary source; Syenza and PharmExec date it Oct 16. Two uses are covered: weight management in adults with obesity or overweight who have at least one weight-related health problem, alongside diet and physical activity; and type 2 diabetes in adults whose blood glucose is not sufficiently controlled, alone when metformin is not appropriate or with other diabetes medicines.
Six tablet strengths, 0.8 mg to 17.2 mg. The opinion rests on two weight studies in 4,740 adults and four diabetes studies in 3,765 adults, compared with placebo, dapagliflozin or oral semaglutide.
According to Syenza, the EC normally decides within 67 days; PharmExec says the EC usually follows within a few weeks. We use 67 days as the outer bound. The date is an estimate, not an EC statement. After the EC decision, price and reimbursement are decided member state by member state.
Oct 15 + 67 days = Dec 21, 2026 (16 + 30 + 21). Estimate.
The meeting recommended six new medicines with no negative opinions on new medicines. If the EC confirms, Foundayo becomes the second oral GLP-1 for weight management in the EU and, unlike the Wegovy pill, also carries a type 2 diabetes label.
Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) was approved by the FDA on Dec 22, 2025 and launched in the US in January 2026. Novo's Sep 30, 2026 press release says it is launched in the US, United Arab Emirates, UK and Germany, with "select markets" to follow "in the coming quarters" (company statement, no dates). The release repeats the existing Boxed Warning for possible thyroid tumors; it is not a new label change.
The UK has sold the pill privately since July 2026, and Germany since Sep 1, 2026, the first EU country to do so, self-pay only. Italy's press expects a launch around October 2026, but AIFA pricing was pending (reported). The tracker is a secondary source dated before the window; it also lists Foundayo's EU status as under review (about 2027), which the Oct 15 CHMP opinion supersedes.
countries approved but not yet launched (Good Fiber tracker, secondary).
NMPA accepted the Wegovy pill application on Aug 27, 2026 (law-firm page). This is a filing, not an approval.
Filed with the FDA for weight management on Dec 18, 2025, with a decision expected in Q4 2026. Pharmaphorum says "December", while pepglp1 says no PDUFA date had been announced as of mid-October. We follow the quarter, not the month. Novo is targeting an early-2027 launch (Reuters, via Yahoo Finance).
Lilly said on Jul 23, 2026 it plans a BLA submission in Q1 2027, according to glp3.wiki. That site's own estimate puts a first decision in late 2027 or early 2028 (estimate).
The material shows no FDA label change for GLP-1 obesity drugs in the window. The nearest is the Mounjaro cardiovascular-risk indication for adults with type 2 diabetes at high cardiovascular risk, approved Aug 28, 2026, before the window (OptiMantra). Rani Therapeutics' RaniPill platform entered the FDA Emerging Technology Program on Oct 5, 2026: a programme acceptance, not a drug approval (MarketBeat).
India's patent lapsed on Mar 20, 2026 and copies launched the next day; China has approved zero generics (BioPharma APAC, Oct 9, 2026). Per PharmaTradz (updated Oct 19), generics are also on sale in Canada, Brazil, South Africa and Saudi Arabia (first launch Sep 16, 2026), while the US, EU, UK and Japan stay protected until about 2031-2032. Prices are in module 6.
Lilly leads on sales and prescriptions, but Q3 results arrive after the window
Module 3 covered which products may be sold and where; this module asks how much they sold and who holds the prescriptions. No Q3 2026 sales were reported inside the window, so every sales figure is Q2 or H1 data.
Q2 2026 sales, $ billions
Lilly vs Novo share of US GLP-1 prescriptions in Q2 2026 (company statement, via CNBC).
Sales and share at a glance
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| Q3 results due | Lilly Oct 29, Novo Nov 4 | 2026 | Scheduled, after window | Zacks |
| Mounjaro + Zepbound sales | $27.7B, about +88%, about 65% of Lilly revenue | H1 2026 | Reported | Zacks |
| Mounjaro / Zepbound sales | $9.9B (+91%) / $4.9B (+44%) | Q2 2026 | Reported | Pharmaceutical Technology |
| Foundayo sales | $98M | Q2 2026 | Reported | Zacks |
| Wegovy + Ozempic sales | DKK 112.2B, about 75.5% of adjusted sales | H1 2026 | Reported | Zacks |
| Lilly US incretin prescription share | 60.9% | June 2026 | Reported | Zacks |
| Wegovy pill US weekly prescriptions | Over 265,000 | Week to Jul 17, 2026 | Reported | Tablets & Capsules |
Detail
Company figures below are reported sales; share figures are prescriptions. The material holds no Lilly or Novo earnings release, so sales sources are secondary. Pluang puts the Q2 tirzepatide total at $14.9B, a rounding-level difference from 9.9 + 4.9 = $14.8B.
Zacks counts $27.7B for H1, about 65% of Lilly revenue, which implies H1 revenue near 27.7 ÷ 0.65 = $42.6B; doubled, $85.2B sits at the low end of the $85-87B 2026 outlook. On the Novo side, Wegovy and Ozempic made DKK 112.2B in H1, so adjusted sales were about 112.2 ÷ 0.755 = DKK 148.6B. Novo's 2026 outlook, even after being raised, is adjusted sales and operating profit between flat and -6% at constant exchange rates (company guidance, via Zacks).
Lilly said in August that it held about 61% of US GLP-1 prescriptions in Q2 against roughly 39% for Novo (company statement, via CNBC). The Zacks figure of 60.9% as of June matches. Zepbound took nearly 60% of branded US obesity prescriptions by the end of Q2, and Lilly's share of international sales was 54.9% in April-May (Zacks).
Lilly CEO Dave Ricks told CNBC that about 700,000 seniors started a GLP-1 once Medicare coverage began in July, and 70% of them are on Lilly drugs (CEO statement, reported around Sept 25, unaudited).
Novo used its Capital Markets Day (about Sept 21, inferred) to promise more than five potential multi-blockbuster launches by 2030 and more than DKK 150B (about $23B) in pipeline sales by 2035. CNBC reports that investors sold the stock, unconvinced by targets matching industry averages and by the lack of a near-term plan.
Novo said in June that US Wegovy pill prescriptions passed 3 million in just over five months, with over 80% going to people new to GLP-1 therapy (secondary summaries). Weekly prescriptions then reached more than 265,000 in the week ending Jul 17, with more than 5 million cumulative.
Early uptake slope of the Wegovy pill against Zepbound and injectable Wegovy (IQVIA National Prescription Audit, data through June 2026).
Q2 sales were $98M. Pharmaceutical Technology puts oral Wegovy at about $850M for H1 and Foundayo just under $100M, all in Q2; the periods differ, so 850 ÷ 98 ≈ 8.7 overstates the gap. Ricks said one-third of new pill patients choose Foundayo (CEO statement). Novo CEO Mike Doustdar says pills could outnumber injectables by the end of the decade (CEO forecast). The authors of the Annals study warn the pill's uptake may not last.
Market-size figures measure different things. Forecasts include $92B for 2026 (IQVIA), $200B by 2030 (J.P. Morgan) and $190B by 2035 (Morgan Stanley), all estimates. Sources also disagree on route: injectables are 83% of sales (Towards Healthcare) or 93% (Grand View, via a Lexaria press release).
IQVIA told a PBMI conference that weight-loss GLP-1s sold $55B over the past 12 months (+75%) and diabetes GLP-1s $98B (+16.5%). Together these total $153B, nearly double Morgan Stanley's $79B, and the article does not state the basis, so we do not use them as market size.
Gallup found 11% of US adults were taking a GLP-1 for weight loss in mid-2026 (July, via Exploding Topics). EY-Parthenon, in a survey of nearly 15,000 people including 3,602 current or former users, found about 54% of semaglutide users take it for weight loss (CBS News, Oct 22, survey-based).
Supply news was enforcement, not scarcity: no new plant in the window, one recall and one warning letter
Module 4 measured how fast demand is growing; this module asks whether supply can follow, and how the unofficial supply from compounders is being policed. No company in the material announced a new plant or opening between Sep 24 and Oct 23.
Capacity and supply at a glance
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| Apothecary Pharma recall | 22 tirzepatide lots plus 1 NAD+ vial | Started Sept 24; Class II Oct 8 | Ongoing | FOX (via FDA notice) |
| Empower warning letter #738238 | 15 working days to respond | Sept 18 | In effect | NASPA |
| 503B bulks-list exclusion | Semaglutide, tirzepatide, liraglutide | Proposed Apr 30; no final decision at Oct 8 | Proposed | NexLife |
| Shortage list | Tirzepatide Dec 19, 2024; semaglutide Feb 21, 2025 | Neither listed as of Apr 2026 | In effect | Health Law Alliance; SmithRx |
| Lilly oral-medicine sites | $16.7B or more | Dates not stated | Reported | Tablets & Capsules |
| Lilly injectable sites | More than $20B, five sites | Dates not stated | Reported | Tablets & Capsules |
| Novo Athlone tableting | $501M or EUR 432M | Date not stated | Reported | Tablets & Capsules; Towards Healthcare |
| Novo oral Wegovy capacity | 10-fold by 2030 | Sept 22 (headline) | Reported | BioSpace |
Detail
According to Tablets & Capsules, Lilly's announcements add up to more than $20 billion across five sites for injectable GLP-1 ingredients, products and devices. For oral Foundayo it lists $6 billion for an API plant in Huntsville, Alabama, $6.5 billion in Houston, $1.2 billion or more in Puerto Rico and $3 billion for an oral-medicines plant in the Netherlands, which sum to 6 + 6.5 + 1.2 + 3 = $16.7 billion or more. Lilly also stockpiled about $1.5 billion of Foundayo inventory before its April 2026 approval.
A Towards Healthcare release of Oct 9 adds more than $3.5 billion for a Pennsylvania injectable site and $4.5 billion for Indiana. The sources do not say whether these overlap with the $20 billion, so we do not add them.
US Wegovy pills are made in Clayton and Durham, North Carolina, with ex-US supply from Athlone, Ireland and Denmark. The Athlone tableting expansion is $501 million in Tablets & Capsules and EUR 432 million in the Oct 9 release; since 501 ÷ 432 ≈ 1.16, it is probably one project (our inference), and neither source gives a date. BioSpace headlined a target of a 10-fold rise in oral Wegovy capacity by 2030 (headline only); CNBC instead reports a tenfold rise in patients, with executives saying supply is not an issue. Neither has a baseline.
Sum of the four commitments below. Cumulative, not an in-window announcement.
Research and Markets, in a paid press release dated Oct 19, values GLP-1 manufacturing at $45.0 billion in 2025, growing 26.0% a year to about $180 billion by 2031 (check: 45.0 × 1.26^6 ≈ 180). It also estimates $18.48 billion of $24.86 billion in 2025 CDMO investment went to US and non-China sites (about 74%). Scope is undefined, so it is not comparable to Towards Healthcare's $52.95 billion drug-market estimate. Leerink's David Risinger expects the small-molecule Foundayo to be cheaper to make at scale than the peptide Wegovy pill (analyst view).
Apothecary Pharma LLC of Cary, North Carolina, began a voluntary nationwide recall on Sept 24 for "lack of assurance of sterility". It covers tirzepatide 18 mg/mL in 4 mL multidose vials, lots AP-202622 to 202625 and 202627 to 202644, plus one NAD+ lot. That is 4 + 18 = 22 lots, 23 with the NAD+ lot; FDA says "22 vials", but USA Today notes the codes suggest 22 lots. FDA classified it Class II on Oct 8 according to FOX and the Boston Globe, and on Oct 10 according to USA Today; we follow Oct 8. The notice reports no illnesses. Mounjaro and Zepbound are unaffected.
FDA's letter #738238 to Empower Pharmacy, a Houston 503A pharmacy, is dated Sept 18 and was reported on Sept 24. FDA found tirzepatide/niacinamide and semaglutide/cyanocobalamin products to be "essentially copies" and said volumes suggest the differences are "pretextual". FDA gave Empower 15 working days to reply; if the letter arrived Sept 18, that clock ran to about Oct 9 (our calculation), and no reply is reported. NASPA and a law-firm note stress this is not a categorical ban on compounding either drug.
22 tirzepatide lots plus 1 NAD+ lot. Beyond-use dates run from Oct 7 to Nov 26; four lots had passed theirs by Oct 24.
FDA sent 30 warning letters to telehealth sellers on Mar 3 and about 25 more on June 8 (law-firm figure). On Apr 30 it proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list; according to NexLife, no final decision existed at Oct 8, and the Fifth Circuit upheld FDA's shortage decisions on Aug 27. Use of compounded drugs has fallen from about 1 in 3 GLP-1 users in 2024 (KFF) to about 1 in 5 (Gallup, July).
FDA declared the tirzepatide shortage over in October 2024 and reaffirmed it on Dec 19, 2024 (SmithRx gives October 2024; we use Dec 19 as the final determination). The semaglutide shortage ended Feb 21, 2025. As of April 2026 neither drug appears on FDA's list, though "localized supply disruptions can still occur". No check dated inside the window was found.
Grace periods for copies ended Mar 5 and Mar 19, 2025 for tirzepatide (503A, 503B) and Apr 24 and May 22, 2025 for semaglutide. One blog gives Apr 22 for 503A semaglutide; we follow Apr 24 from two law-firm sources.
With no shortage, compounding rests on the individualized-prescription argument, which the Empower letter attacks directly. Every figure in this module is secondary, and most plant figures are undated.
The price now depends on the channel: Medicare pays $50, cash buyers $149 to $449, and commercial coverage is retreating
Module 5 covered how much drug can be made; this module covers who pays for it and how much. Every price carries its channel and the date it was checked.
Coverage and pricing at a glance
| Item | Key figure | Date | Status | Source |
|---|---|---|---|---|
| Medicare GLP-1 Bridge | $50 copay; net price $245 | Jul 1, 2026 to Dec 31, 2027 | In effect | MyClearMatch |
| Medicaid obesity coverage | About 13 state programs | Jan 2026 | Reported | YourHealthier |
| TrumpRx.gov cash target | ~$350 toward ~$245 | Launched Feb 5, 2026 | Target (estimate) | JumpstartMD |
| Wegovy pen / Zepbound, cash | $349 / $399 | Oct 19, 2026 | In effect | GLP Chart |
| Zepbound commercial coverage | 60% uncovered | Jul 2026 | Reported | GoodRx |
| Employer plans | ≥10% may drop coverage in 2027 | 2026 survey | Reported | Vox |
Detail by channel
A CMS demonstration outside Part D, ending Dec 31, 2027. Eligible beneficiaries pay a flat $50 per monthly supply; according to MyClearMatch, the government negotiated a $245 net price with Novo Nordisk and Eli Lilly. Covered are Wegovy (injection and tablet), the Zepbound KwikPen and Foundayo, not Ozempic or Mounjaro. Eligibility is tiered by BMI at the start of therapy: 35 or higher; 30 or higher plus a listed condition such as uncontrolled hypertension; or 27 or higher plus prediabetes or a prior heart attack or stroke. The copay does not count toward the $2,100 Part D out-of-pocket cap.
Only about 13 state Medicaid fee-for-service programs covered obesity GLP-1s as of January 2026; JumpstartMD says this was down from 16. TrumpRx.gov launched Feb 5, 2026; cash prices are expected to start near $350 and fall toward $245 over about two years, a target and not a current price. EY-Parthenon, via CBS, says the administration's agreement with the two makers cut prices to $150-$350 a month from roughly $1,000. No official TrumpRx or CMS page is in the material.
IQVIA's Scott Biggs cited 9,000 paid claims and "almost $2 million" from CMS.
A Medicare patient has a flat, published copay. The Bridge is a time-limited demonstration, so the price is known only to the end of 2027.
List prices were about $1,349 for Wegovy and $1,086 for Zepbound in June 2026 (JumpstartMD); YourHealthier gives $1,350 and $1,060. Cash saves a lot: 12 × $349 = $4,188 a year for the Wegovy pen, against 12 × $1,349 = $16,188 at list, about 74% less. A commercial copay after prior authorization is about $25, but savings cards cannot be used under Medicare, Medicaid, VA or TRICARE.
NovoCare's $199 starter offer ended June 30, 2026. June LillyDirect vial prices ($299, $399, $449) were not re-checked in October. Compounded semaglutide is advertised from $76 all-in, but is not FDA-approved.
The Wegovy pill has sold in Germany since Sept 1, 2026 for about EUR 170-280 a month, self-pay only. UK sales of the Wegovy pill (since July) and Foundayo (since August) are private, not NHS, and the material gives no UK price. Health Canada approved the first generic semaglutide on Apr 28, 2026; Canadian generics typically sell 45-90% below brand.
Zepbound is uncovered for 60% of commercial lives, up from 51% in 2025 (over 114 million people, 17 million more), with restricted coverage down from 45% to 37%. For Wegovy, 27 million are uncovered; over 66 million lack Foundayo cover; 88% of covered patients face prior authorization or similar rules. The figures are consistent: 114M ÷ 0.60 ≈ 190M commercial lives.
GoodRx reports Cigna stopped covering Wegovy and Zepbound for employees (date not stated) and CVS Caremark returns Zepbound to its standard formulary in October 2026, day not given, so we cannot confirm it is in effect. A GEHA plan document shows the pattern: from Jan 1, 2026 Wegovy was non-preferred and Zepbound non-formulary, needing an exception.
of covering plans likely to stop in 2027 (Business Group on Health survey).
Vox, undated, reports about two-thirds of private employer plans covered weight-loss GLP-1s in 2026; PepsiCo, Starbucks and Lowe's are reportedly cutting. Nearly 8 in 10 employers say GLP-1s raise costs.
Access and price, not approval or efficacy, now decide who gets a GLP-1
Modules 2 to 6 covered the trials, the decisions, the sales, the supply and the prices. This module turns them into three changes, a reader-by-reader view and a dated watch-list, using only facts from those modules.
The CHMP backed Foundayo on Oct 15, the Wegovy pill is launched in four markets, and only 2 of 16 European countries had it on sale in Sept 2026.
A heart-safety result for an oral drug, and the first randomized data on limiting regain, such as Fractyl's regain figures (Oct 16, 2026).
Medicare and cash prices are published, while commercial coverage shrinks: Zepbound is uncovered for 60% of commercial lives (Jul 2026).
What it means by reader
Patients in the US
What changed. Medicare Bridge has run since Jul 1 with a $50 copay; cash prices are $349 for the Wegovy pen and from $149 for the Wegovy pill.
Implication. The route to a GLP-1 depends on the payer: a Medicare patient and a cash buyer have a published price, a commercially insured patient faces a plan decision.
Patients in Europe
What changed. Foundayo has a CHMP opinion; the Wegovy pill is approved in 15 of 16 tracked countries but on sale in 2.
Implication. Access depends on national launch and pricing, and Germany's pill is self-pay at about EUR 170-280 a month.
Payers and employers
What changed. Zepbound is uncovered for 60% of commercial lives; at least 10% of covering plans may stop in 2027.
Implication. Coverage is a cost decision under pressure; the Bridge ends Dec 31, 2027.
Investors
What changed. Lilly leads Q2 sales about 1.9 times and prescriptions about 61% to 39%; Novo guides adjusted sales flat to -6%.
Implication. Q3 results on Oct 29 and Nov 4 will test whether the lead widens; the Foundayo ramp ($98M in Q2) is the number to watch. This page gives no investment advice.
Compounders and telehealth sellers
What changed. FDA's Empower letter calls products "essentially copies"; a sterility recall is ongoing; no shortage is listed.
Implication. Compounding rests on the individualized-prescription argument, which FDA is attacking.
Implications restate facts from modules 2 to 6. This page is information, not medical or investment advice.
Key dates
Dates already past on Oct 24, 2026 are marked In effect; later dates are Upcoming. Dates marked as estimates are ours or a secondary source's, not an agency's.
| Date | Event | State on Oct 24, 2026 | Source |
|---|---|---|---|
| Jul 1, 2026 | Medicare GLP-1 Bridge starts ($50 copay) | In effect | MyClearMatch |
| Sep 1, 2026 | Wegovy pill on sale in Germany, self-pay | In effect | Good Fiber |
| Sep 18, 2026 | FDA warning letter #738238 to Empower Pharmacy | In effect | NASPA |
| Sep 24, 2026 | Apothecary Pharma recall begins (Class II on Oct 8) | In effect | FOX |
| Sep 30, 2026 | Wegovy pill launched in US, UAE, UK and Germany; ACHIEVE-4 released | In effect | Novo (PRNewswire); Lilly |
| Oct 15, 2026 | CHMP positive opinion for Foundayo | In effect | EMA |
| Oct 2026 (day not stated) | CVS Caremark returns Zepbound to its standard formulary | Unconfirmed; day not stated | GoodRx |
| Oct 26, 2026 | Zenagamtide AMBIENCE trial registered to start | Upcoming | Synapse |
| Oct 29, 2026 | Lilly Q3 2026 results | Upcoming | Zacks |
| Nov 4, 2026 | Novo Q3 2026 results | Upcoming | Zacks |
| About Dec 21, 2026 | Latest likely EC decision on Foundayo (estimate: Oct 15 + 67 days) | UpcomingEstimate | Syenza |
| Q4 2026 | FDA decision on CagriSema, no PDUFA date published | Upcoming | pepglp1 |
| Late Q4 2026 | Fractyl plans De Novo submission for Revita | Upcoming | Fractyl |
| Q1 2027 | Retatrutide BLA planned; REMAIN-1 12-month endpoint planned | Upcoming | glp3.wiki; Fractyl |
| 2027 | At least 10% of covering employer plans may drop coverage | UpcomingSurvey estimate | Vox |
| Dec 31, 2027 | Medicare GLP-1 Bridge ends | Upcoming | MyClearMatch |